---
title: "Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293395375.md"
description: "The NMPA has approved the supplemental application for the use of Toripalimab in combination with chemotherapy as a perioperative treatment for resectable stage Ⅱ-Ⅲ NSCLC. This decision allows for the treatment to be used in patients with these specific stages of non-small cell lung cancer."
datetime: "2026-07-21T23:12:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293395375.md)
  - [en](https://longbridge.com/en/news/293395375.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293395375.md)
generator: "portal-rs"
---

# Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

The NMPA has approved the supplemental application for the use of Toripalimab in combination with chemotherapy as a perioperative treatment for resectable stage Ⅱ-Ⅲ NSCLC. This decision allows for the treatment to be used in patients with these specific stages of non-small cell lung cancer.

### Related Stocks

- [01877.HK](https://longbridge.com/en/quote/01877.HK.md)
- [688180.CN](https://longbridge.com/en/quote/688180.CN.md)

## Related News & Research

- [Junshi Biosciences terminates 2026 A-share employee stock ownership scheme](https://longbridge.com/en/news/297027904.md)
- [Shanghai Junshi says China regulator accepts label expansion filing for toripalimab chemo in resectable stage II-III NSCLC](https://longbridge.com/en/news/293348759.md)
- [Akeso says Phase III ivonescimab-chemo trial in biliary tract cancer meets overall survival endpoint](https://longbridge.com/en/news/297257007.md)
- [AKESO  Ivonescimab Plus Chemotherapy Phase III Study Meets Primary Overall Survival Endpoint](https://longbridge.com/en/news/296969973.md)
- [Ivonescimab regimen shows OS superiority in Phase III HARMONi-GI1, Summit Therapeutics notes](https://longbridge.com/en/news/297053863.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**